Physician profile
Christopher Pickett
NPI 1609072693
$8,864.58
in general payments reported to CMS, 2019-2025
29 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,704 · 2020: $920 · 2021: $456 · 2022: $2,082 · 2023: $1,173 · 2024: $1,102 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,420.33 | 2019 | |
| Boston Scientific Corporation | $1,405.47 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Opticross |
| Edwards Lifesciences Corporation | $1,299.67 | 2022-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $1,277.39 | 2021-2025 | Corevalve Evolut R |
| Abbott Laboratories | $1,140.42 | 2019-2025 | Ensite, Navitor, Gallant |
| Abiomed | $795.91 | 2020-2022 | |
| Inari Medical, INC. | $493.08 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Acist Medical Systems, INC. | $181.97 | 2023-2024 | |
| Penumbra, INC. | $150.17 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.32 | 2023-2024 | Lifevest |
| Stryker Corporation | $112.23 | 2020 | |
| Medtronic Vascular, INC. | $105.29 | 2019-2020 | |
| Cardiva Medical, INC. | $40.72 | 2022 | |
| Heartflow, INC. | $37.34 | 2022 | |
| Irhythm Technologies, INC. | $33.51 | 2024 | Zio Monitor, Zio Xt Patch |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.23 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $25.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.56 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $23.06 | 2023 | Verquvo |
| Altathera Pharmaceuticals LLC | $22.55 | 2024 | Sotalol Hydrochloride |
| Teleflex LLC | $22.09 | 2024 | Guideliner |
| Janssen Pharmaceuticals, INC | $21.63 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $18.85 | 2024 | Arcalyst |
| Agepha Pharma Fz LLC | $15.63 | 2024 | Lodoco |
| Chiesi USA, INC. | $15.05 | 2024 | Kengreal |
| Cook Medical LLC | $12.77 | 2023 | Evolution |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pickett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.